Drug profile · INN
selumetinib
KOSELUGO
selumetinib (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — selumetinib
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
selumetinib (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Frequently asked questions
What is selumetinib?
selumetinib (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selumetinib?
KOSELUGO is a marketed brand name for selumetinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selumetinib?
selumetinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.